학술논문

Systematic review: psychological morbidity in young people with inflammatory bowel disease - risk factors and impacts.
Document Type
Article
Source
Alimentary Pharmacology & Therapeutics. Jul2016, Vol. 44 Issue 1, p3-15. 13p.
Subject
*INFLAMMATORY bowel diseases
*ULCERATIVE colitis diagnosis
*INTESTINAL disease diagnosis
*ANXIETY diagnosis
*SYMPTOMS
*DISEASE risk factors
Language
ISSN
0269-2813
Abstract
Background Psychological morbidity in young people aged 10-24 years, with inflammatory bowel disease (IBD) is increased, but risk factors for and impacts of this are unclear. Aim To undertake a systematic literature review of the risk factors for and impact of psychological morbidity in young people with IBD. Methods Electronic searches for English-language articles were performed with keywords relating to psychological morbidity according to DSM-IV and subsequent criteria; young people; and IBD in the MEDLINE, PsychInfo, Web of Science and CINAHL databases for studies published from 1994 to September 2014. Results One thousand four hundred and forty-four studies were identified, of which 30 met the inclusion criteria. The majority measured depression and anxiety symptoms, with a small proportion examining externalising behaviours. Identifiable risk factors for psychological morbidity included: increased disease severity ( r2 = 0.152, P < 0.001), lower socioeconomic status ( r2 = 0.046, P < 0.001), corticosteroids ( P ≤ 0.001), parental stress ( r = 0.35, P < 0.001) and older age at diagnosis ( r = 0.28, P = 0.0006). Impacts of psychological morbidity in young people with IBD were wide-ranging and included abdominal pain ( r = 0.33; P < 0.001), sleep dysfunction ( P < 0.05), psychotropic drug use (HR 4.16, 95% CI 2.76-6.27), non-adherence to medication (12.6% reduction) and negative illness perceptions ( r = −0.43). Conclusions Psychological morbidity affects young people with IBD in a range of ways, highlighting the need for psychological interventions to improve outcomes. Identified risk factors provide an opportunity to develop targeted therapies for a vulnerable group. Further research is required to examine groups under-represented in this review, such as those with severe IBD and those from ethnic minorities. [ABSTRACT FROM AUTHOR]